Protective effect of a protein-bound polysaccharide, PSK, on CLP-induced sepsis in mice transplanted orthotopically with colon tumor

Shock

Volumn 25, Issue 1, 2006, Pages 36-42

  Ohmura, Yoshio ^a   Matsunaga, Kenichi ^a   Suzuki, Tatsuo ^b  

^a KUREHA CORPORATION   (Japan)

^b KITASATO UNIVERSITY MEDICAL CENTER   (Japan)

Author keywords

CLP; IFN ; IL 10; Orthotopic tumor transplantation; PSK; Sepsis

Indexed keywords

BIOLOGICAL RESPONSE MODIFIER; GAMMA INTERFERON; INTERLEUKIN 10; KRESTIN; PROTEOGLYCAN; PS-K;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; CANCER TRANSPLANTATION; CD4+ T LYMPHOCYTE; COLON TUMOR; DRUG EFFECT; EXPERIMENTAL NEOPLASM; FEMALE; GENE EXPRESSION REGULATION; IMMUNOLOGY; METHODOLOGY; MOUSE; PATHOLOGY; SEPSIS; SPLEEN;

ANIMALS; BIOLOGICAL RESPONSE MODIFIERS; CD4-POSITIVE T-LYMPHOCYTES; COLONIC NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION; INTERFERON TYPE II; INTERLEUKIN-10; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; PROTEOGLYCANS; SEPSIS; SPLEEN;

EID: 33646383888     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.shk.0000186929.57109.c4     Document Type: Article

References (36)

1. Poll T: Immunotherapy of sepsis. Lancet Infect Dis 1:165-174, 2001.
2. Riedemann NC, Guo RF, Ward PA: Novel strategies for the treatment of sepsis. Nat Med 9:517-524, 2003.
3. Kobayashi H, Matsunaga K, Oguchi Y: Anti-metastatic effects of PSK (Krestin), a protein-bound polysaccharide obtained from basidiomycetes, an overreview. Cancer Epidemiol Biomarkers Prev 4:275-281, 1995.
4. Tsukagoshi S, Hashimoto Y, Fujii G, Kobayashi H, Nomoto K, Orita K: Krestin (PSK). Cancer Treat Rev 11:131-155, 1984.
5. Mayer P, Drews J: The effect of a protein-bound polysaccharide from Coriolus versicolor on immunological parameters and experimental infection in mice. Infection 8:13-20, 1980.
6. Ebihara K, Minamishima Y: Protective effect of biological response modifiers on murine cytomegalovirus. J Virol 51:117-122, 1984.
7. Ohmura Y, Matsunaga K, Motokawa I, Sakurai K, Ando T: Protective effects of a protein-bound polysaccharide, PSK, on Candida albicans infection in mice via tumor necrosis factor-αinduction. Int Immunopharmacol 1:1797-1811, 2001.
8. Ohmura Y, Matsunaga K, Motokawa I, Sakurai K, Ando T: Protective effects of a protein-bound polysaccharide, PSK, against Candida albicans infection in syngeneic tumor-bearing mice via Th1 cell functions. Cancer Biother Radiopharm 18:769-780, 2003.
9. Harada M, Matsunaga K, Oguchi Y, Iijima H, Ito O, Tamada K, Kimura G, Nomoto K: The involvement of transforming growth factor-β in the impaired antitumor T-cell response at the gut-associated lymphoid tissue (GALT). Cancer Res 55:6146-6151, 1995.
10. Baker CC, Chaudry IH, Gaines HO, Baue AE: Evaluation of factors affecting mortality rate after sepsis in a murine cecal ligation and puncture model. Surgery 94:331-335, 1983.
11. Chromczynski P, Sacchi N: Single-step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156-159, 1987.
12. Harada M, Tamada K, Abe K, Yasumoto K, Kimura G, Nomoto K: Role of the endogenous production of interleukin 12 in immunotherapy. Cancer Res 58:3073-3077, 1998.
13. Gajewski TF, Fitch FW: Anti-proliferative effect of IFN-γ in immune regulation. 1. IFN-γ inhibits the proliferation of Th2 but not Th1 murine helper T cell clones. J Immunol 140:4245-4252, 1988.
14. Lee FF, Yokota T, Otsuka T, Meyerson P, Villaret D, Coffman R, Mossmann T, Rennick D, Roehm N, Smith C, Zlotnil A, Arai K: Isolation and characterization of a mouse interleukin cDNA clone that expresses B-cell stimulatory factor 1 activities and T-cell- and mast-cell-stimulating activities. Proc Natl Acad Sci USA 83:2061-2065, 1986.
15. Singleton KD, Wischmeyer PE: Distance of cecum ligated influences mortality, tumor necrosis factor-α and interleukin-6 expression following cecal ligation and puncture in the rat. Eur Surg Res 35:486-491, 2003.
16. Otero-Anton E, Gonzalez-Quintela A, Lopez-Soto A, Lopez-Ben S, Llovo J, Perez LF: Cecal ligation and puncture as a model of sepsis in the rat: influence of the puncture size on mortality, bacteremia and tumor necrosis factor α levels. Eur Surg Res 33:77-79, 2001.
17. Remick DG, Newcomb DE, Bolgos GL, Call DR: Comparison of the mortality and inflammatory response of two models of sepsis: lipopolysaccharide vs. cecal ligation and puncture. Shock 13:110-116, 2000.
18. Sasaki H, Kobayashi M, Emori Y, Ohya O, Hayashi Y, Nomoto K: Z-100, a polysaccharide-rich preparation extracted from the human type Mycobacterium tuberculosis, improves the resistance of Meth-A tumor-bearing mice to endogenous septic infection. Biotherapy (Netherlands) 10:139-143, 1997.
19. Emori Y, Oka H, Ohya O, Tamaki H, Hayashi Y, Nomoto K: The protective effect of royal jelly on cecal ligation and puncture-induced sepsis in X-irradiated mice. Biotherapy (Tokyo) 12:1143-1148, 1998.
20. Mendez MV, Molloy RG, O'Riordain DS, Holtzheimer RG, Nestor MS, Obando A, Saporoschetz I, Schoof DD, Mannick JA, Rodrick ML: Lymphokine activated killer cells enhance IL-2 prevention of sepsis-related death in a murine model of thermal injury. J Surg Res 54:565-570, 1993.
21. Morikawa K, Walker SM, Nakajima M, Pathak S, Jwssup JM, Fidler IJ: Influence of organ environment on the growth, selection, and metastasis of human colon carcinoma cells in nude mice. Cancer Res 48:6863-6871, 1988.
22. Walley KR, Lukacs NW, Standiford TJ, Strieter RM, Kunkel SL: Balance of inflammatory cy tokines related to severity and mortality of murine sepsis. Infect Immun 64:4733-4738, 1996.
23. Reddy RC, Chen GH, Tekchandani PK, Standiford TJ: Sepsis-induced immunosuppression: from bad to worse. Immunol Res 24:273-287, 2001.
24. Maier S, Traeger T, Entleutner M, Westerholt A, Kleist B, Huser N, Holzmann B, Stier A, Pfeffer K, Heidecke CD: Cecal ligation and puncture versus colon ascendens stent peritonitis: two distinct animal models for polymicrobial sepsis. Shock 21:505-511, 2004.
25. Turnbull IR, Javadi P, Buchman TG, Hotchkiss RS, Karl IE, Coopersmith CM: Antibiotics improve survival in sepsis independent of injury severity but do not change mortality in mice with markedly elevated interleukin 6 levels. Shock 21:121-125, 2004.
26. Conti P, Kempuraj D, Kandere K, Di Gioacchino M, Barbacane RC, Castellani ML, Felaco M, Boucher W, Letourneau R, Theoharides TC: IL-10, an inflammatory/inhibitory cytokine, but not always. Immunol Lett 86:123-129, 2003.
27. Poll T, Marchant A, Buurman WA, Berman L, Keogh CV, Lazarus DD, Nguyen L, Goldman M, Moldawer LL, Lowry SF: Endogenous IL-10 protects mice from death during septic peritonitis. J Immunol 155:5397-5401, 1995.
28. Standiford TJ, Strieter RM, Lukacs NW, Kunkel SL: Neutralization of IL-10 increases lethality in endoxemia. Cooperative effects of macrophage inflammatory protein-2 and tumor necrosis factor. J Immunol 155:2222-2229, 1995.
29. Song GY, Chung CS, Chaudry IH, Ayala A: What is the role of interleukin-10 in polymicrobial sepsis: anti-inflammatory agent or immunosuppressant? Surgery 126:378-383, 1999.
30. Kalechmann Y, Gafter U, Gal R, Rushkin G, Yan D, Albeck M, Sredni B: Anti-IL-10 therapeutic strategy using the immunomodulator AS101 in protecting mice from sepsis-induced death: dependence on timing of immunomodulating intervention. J Immunol 169:384-392, 2002.
31. Williams DL, Li C, Ha T, Ozment-Skelton T, Kalbfleisch JH, Preiszner J, Brooks L, Breuel K, Schweitzer JB: Modulation of the phosphoinsitide 3-kinase pathway alters innate resistance to polymicrobial sepsis. J Immunol 172:449-456, 2004.
32. Urano M, Tanaka C, Sugiyama Y, Miya K, Saji S: Antitumor effects of residual tumor after cryoablation: the combined effect of residual tumor and a protein-bound polysaccharide on multiple liver metastases in a murine model. Cryobiology 46:238-245, 2003.
33. Shibata M, Nezu T, Kanou H, Nagata Y, Kimura T, Takekawa M, Ando K, Fukuzawa M: Immunomodulatory effects of low dose cis-diaminedichloro-platinum (cisplatin) combined with UFT and PSK in patients with advanced colorectal cancer. Cancer Invest 20:166-173, 2002.
34. Kanazawa M, Yoshihara K, Abe H, Iwadate M, Watanabe K, Suzuki S, Endoh Y, Takita K, Sekikawa K, Takenoshita S, Ogata T, Ohto H: Effects of PSK on T and dendritic cells differentiation in gastric or colorectal cancer patients. Anticancer Res 25:443-449, 2005.
35. Berenson LS, Ota N, Murphy KM: Issues in T-helper 1 development-resolved and unresolved. Immunol Rev 202:157-174, 2004.
36. Endoh H, Matsunaga K, Yoshikumi C, Kawai Y, Suzuki T, Nomoto K: Production of antiserum against antitumor protein-bound polysaccharide preparation PSK (Krestin) and its pharmaceutical application. Int J Immunopharmacol 10:103-109, 1987.